The latest price target for Amgen (NASDAQ:AMGN) was reported by Jefferies on November 12, 2024. The analyst firm set a price target for $380.00 expecting AMGN to rise to within 12 months (a possible 26.66% upside). 41 analyst firms have reported ratings in the last year.

The latest analyst rating for Amgen (NASDAQ:AMGN) was provided by Jefferies, and Amgen maintained their buy rating.

The last upgrade for Amgen Inc happened on May 3, 2024 when William Blair raised their price target to N/A. William Blair previously had a market perform for Amgen Inc.

The last downgrade for Amgen Inc happened on October 14, 2024 when Truist Securities changed their price target from $320 to $333 for Amgen Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amgen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amgen was filed on November 12, 2024 so you should expect the next rating to be made available sometime around November 12, 2025.

While ratings are subjective and will change, the latest Amgen (AMGN) rating was a maintained with a price target of $380.00 to $380.00. The current price Amgen (AMGN) is trading at is $300.01, which is out of the analyst’s predicted range.